{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T23:01:26Z","timestamp":1781478086857,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1245\/s10434-025-18427-x","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:41:35Z","timestamp":1759174895000},"page":"426-434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Radiologic and Pathologic Response as Predictors of Survival in Patients with Colorectal Peritoneal Metastases Undergoing Neoadjuvant Chemotherapy Followed by CRS-HIPEC: A Retrospective Study"],"prefix":"10.1245","volume":"33","author":[{"given":"Jessica","family":"Cyr-Cronier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Lebel-Guay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Sideris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai-Kim","family":"Gervais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Dub\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika\u00ebl","family":"Lefebvre-Soucisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"18427_CR1","unstructured":"World Health Organization. Colorectal cancer. Geneva: WHO; 2023; https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/colorectal-cancer"},{"key":"18427_CR2","unstructured":"Canadian Cancer Statistics Advisory Committee in collaboration with the Canadian Cancer Society. Statistics Canada and the Public Health Agency of Canada. November 2023."},{"issue":"11","key":"18427_CR3","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1002\/ijc.25596","volume":"128","author":"VE Lemmens","year":"2011","unstructured":"Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer. 2011;128(11):2717\u201325. https:\/\/doi.org\/10.1002\/ijc.25596.","journal-title":"Int J Cancer."},{"issue":"8","key":"18427_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/DCR.0000000000000412","volume":"58","author":"P Quere","year":"2015","unstructured":"Quere P, Facy O, Manfredi S, et al. Epidemiology, management, and survival of peritoneal carcinomatosis from colorectal cancer: a population-based study. Dis Colon Rectum. 2015;58(8):743\u201352. https:\/\/doi.org\/10.1097\/DCR.0000000000000412.","journal-title":"Dis Colon Rectum."},{"issue":"5","key":"18427_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/bjs.8679","volume":"99","author":"J Segelman","year":"2012","unstructured":"Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99(5):699\u2013705. https:\/\/doi.org\/10.1002\/bjs.8679.","journal-title":"Br J Surg."},{"issue":"3","key":"18427_CR6","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1245\/s10434-023-14608-8","volume":"31","author":"E Sarfaty","year":"2024","unstructured":"Sarfaty E, Khajoueinejad N, Yu AT, et al. Actual 5-year survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for patients with peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2024;31(3):1970\u20139. https:\/\/doi.org\/10.1245\/s10434-023-14608-8.","journal-title":"Ann Surg Oncol."},{"issue":"8","key":"18427_CR7","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1001\/jamaoncol.2021.0580","volume":"7","author":"RM van Stein","year":"2021","unstructured":"van Stein RM, Aalbers AGJ, Sonke GS, van Driel WJ. Hyperthermic intraperitoneal chemotherapy for ovarian and colorectal cancer: a review. JAMA Oncol. 2021;7(8):1231\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0580.","journal-title":"JAMA Oncol."},{"issue":"3","key":"18427_CR8","first-page":"207","volume":"41","author":"D Elias","year":"1994","unstructured":"Elias D, Detroz B, Debaene B, et al. Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia: reliable and unreliable concepts. Hepatogastroenterology. 1994;41(3):207\u201313.","journal-title":"Hepatogastroenterology."},{"issue":"1","key":"18427_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.2009.23.9285","volume":"28","author":"D Elias","year":"2010","unstructured":"Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28(1):63\u20138. https:\/\/doi.org\/10.1200\/JCO.2009.23.9285.","journal-title":"J Clin Oncol."},{"issue":"2","key":"18427_CR10","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/SLA.0b013e3182263933","volume":"254","author":"F Quenet","year":"2011","unstructured":"Quenet F, Goere D, Mehta SS, et al. Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Ann Surg. 2011;254(2):294\u2013301. https:\/\/doi.org\/10.1097\/SLA.0b013e3182263933.","journal-title":"Ann Surg."},{"issue":"20","key":"18427_CR11","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2003.04.187","volume":"21","author":"VJ Verwaal","year":"2003","unstructured":"Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737\u201343. https:\/\/doi.org\/10.1200\/JCO.2003.04.187.","journal-title":"J Clin Oncol."},{"issue":"2","key":"18427_CR12","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(20)30599-4","volume":"22","author":"F Quenet","year":"2021","unstructured":"Quenet F, Elias D, Roca L, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):256\u201366. https:\/\/doi.org\/10.1016\/S1470-2045(20)30599-4.","journal-title":"Lancet Oncol."},{"issue":"3","key":"18427_CR13","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1200\/JCO.22.01690","volume":"41","author":"VK Morris","year":"2023","unstructured":"Morris VK, Kennedy EB, Baxter NN, et al. Treatment of metastatic colorectal cancer: ASCO guideline. J Clin Oncol. 2023;41(3):678\u2013700. https:\/\/doi.org\/10.1200\/JCO.22.01690.","journal-title":"J Clin Oncol."},{"issue":"8","key":"18427_CR14","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386\u2013422. https:\/\/doi.org\/10.1093\/annonc\/mdw235.","journal-title":"Ann Oncol."},{"key":"18427_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/jso.27776","author":"N Tinsley","year":"2024","unstructured":"Tinsley N, O\u2019Dwyer ST, Nagaraju R, et al. Preoperative chemotherapy response and survival in patients with colorectal cancer peritoneal metastases. J Surg Oncol. 2024. https:\/\/doi.org\/10.1002\/jso.27776.","journal-title":"J Surg Oncol."},{"issue":"7","key":"18427_CR16","doi-asserted-by":"publisher","first-page":"3840","DOI":"10.1245\/s10434-020-09330-8","volume":"28","author":"A Bhatt","year":"2021","unstructured":"Bhatt A, Rousset P, Benzerdjeb N, et al. Clinical and radiologic predictors of a pathologic complete response to neoadjuvant chemotherapy (NACT) in patients undergoing cytoreductive surgery for colorectal peritoneal metastases: results of a prospective multi-center study. Ann Surg Oncol. 2021;28(7):3840\u20139. https:\/\/doi.org\/10.1245\/s10434-020-09330-8.","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"18427_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer."},{"issue":"4","key":"18427_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/jso.21068","volume":"98","author":"AG Portilla","year":"2008","unstructured":"Portilla AG, Shigeki K, Dario B, Marcello D. The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol. 2008;98(4):228\u201331. https:\/\/doi.org\/10.1002\/jso.21068.","journal-title":"J Surg Oncol."},{"issue":"1","key":"18427_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/SLA.0b013e318255486a","volume":"256","author":"G Passot","year":"2012","unstructured":"Passot G, Vaudoyer D, Cotte E, et al. Progression following neoadjuvant systemic chemotherapy may not be a contraindication to a curative approach for colorectal carcinomatosis. Ann Surg. 2012;256(1):125\u20139. https:\/\/doi.org\/10.1097\/SLA.0b013e318255486a.","journal-title":"Ann Surg."},{"issue":"8","key":"18427_CR20","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1245\/s10434-014-3647-0","volume":"21","author":"G Passot","year":"2014","unstructured":"Passot G, You B, Boschetti G, et al. Pathological response to neoadjuvant chemotherapy: a new prognosis tool for the curative management of peritoneal colorectal carcinomatosis. Ann Surg Oncol. 2014;21(8):2608\u201314. https:\/\/doi.org\/10.1245\/s10434-014-3647-0.","journal-title":"Ann Surg Oncol."},{"issue":"13","key":"18427_CR21","doi-asserted-by":"publisher","first-page":"9138","DOI":"10.1245\/s10434-021-10367-6","volume":"28","author":"E Mor","year":"2021","unstructured":"Mor E, Assaf D, Laks S, et al. Ratio of pathological response to preoperative chemotherapy in patients undergoing complete cytoreduction and hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer correlates with survival. Ann Surg Oncol. 2021;28(13):9138\u201347. https:\/\/doi.org\/10.1245\/s10434-021-10367-6.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"18427_CR22","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1245\/s10434-023-13150-x","volume":"30","author":"F Fanget","year":"2023","unstructured":"Fanget F, Kefleyesus A, Peron J, et al. Comparison of neoadjuvant systemic chemotherapy protocols for the curative-intent management of peritoneal metastases from colorectal cancer, regarding morphological response, pathological response, and long-term outcomes: a retrospective study. Ann Surg Oncol. 2023;30(6):3304\u201315. https:\/\/doi.org\/10.1245\/s10434-023-13150-x.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"18427_CR23","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1002\/ijc.34636","volume":"153","author":"P Marolleau","year":"2023","unstructured":"Marolleau P, Tougeron D, Allignet B, et al. Complete pathological response after chemotherapy or immune checkpoint inhibitors in deficient MMR metastatic colorectal cancer: Results of a retrospective multicenter study. Int J Cancer. 2023;153(7):1376\u201385. https:\/\/doi.org\/10.1002\/ijc.34636.","journal-title":"Int J Cancer."},{"issue":"24","key":"18427_CR24","doi-asserted-by":"publisher","first-page":"6238","DOI":"10.3390\/cancers14246238","volume":"14","author":"M Karimi","year":"2022","unstructured":"Karimi M, Osterlund P, Hammarstrom K, Imam I, Frodin JE, Glimelius B. Associations between response to commonly used neo-adjuvant schedules in rectal cancer and routinely collected clinical and imaging parameters. Cancers (Basel). 2022;14(24):6238. https:\/\/doi.org\/10.3390\/cancers14246238.","journal-title":"Cancers (Basel)."},{"key":"18427_CR25","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3389\/fonc.2019.00497","volume":"9","author":"Y Tan","year":"2019","unstructured":"Tan Y, Fu D, Li D, et al. Predictors and risk factors of pathologic complete response following neoadjuvant chemoradiotherapy for rectal cancer: a population-based analysis. Front Oncol. 2019;9:497. https:\/\/doi.org\/10.3389\/fonc.2019.00497.","journal-title":"Front Oncol."},{"issue":"6","key":"18427_CR26","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1097\/DCR.0b013e3182837e5b","volume":"56","author":"JW Huh","year":"2013","unstructured":"Huh JW, Kim HR, Kim YJ. Clinical prediction of pathological complete response after preoperative chemoradiotherapy for rectal cancer. Dis Colon Rectum. 2013;56(6):698\u2013703. https:\/\/doi.org\/10.1097\/DCR.0b013e3182837e5b.","journal-title":"Dis Colon Rectum."},{"key":"18427_CR27","doi-asserted-by":"publisher","first-page":"1587684","DOI":"10.3389\/fmed.2025.1587684","volume":"12","author":"M Liu","year":"2025","unstructured":"Liu M, Zhou Q, Lan B, Gan J, Zhang S. Factors influencing pathological complete response following neoadjuvant chemoimmunotherapy in locally advanced microsatellite stable colorectal cancer: a retrospective analysis. Front Med (Lausanne). 2025;12:1587684. https:\/\/doi.org\/10.3389\/fmed.2025.1587684.","journal-title":"Front Med (Lausanne)."},{"issue":"8","key":"18427_CR28","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1038\/s41591-022-01930-z","volume":"28","author":"WK Chatila","year":"2022","unstructured":"Chatila WK, Kim JK, Walch H, et al. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer. Nat Med. 2022;28(8):1646\u201355. https:\/\/doi.org\/10.1038\/s41591-022-01930-z.","journal-title":"Nat Med."},{"issue":"5","key":"18427_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.21037\/atm.2020.01.52","volume":"8","author":"ZP Li","year":"2020","unstructured":"Li ZP, Liu XY, Kao XM, et al. Clinicopathological characteristics and prognosis of colorectal mucinous adenocarcinoma and nonmucinous adenocarcinoma: a surveillance, epidemiology, and end results (SEER) population-based study. Ann Transl Med. 2020;8(5):205. https:\/\/doi.org\/10.21037\/atm.2020.01.52.","journal-title":"Ann Transl Med."},{"issue":"15","key":"18427_CR30","doi-asserted-by":"publisher","first-page":"e658","DOI":"10.1097\/MD.0000000000000658","volume":"94","author":"JS Park","year":"2015","unstructured":"Park JS, Huh JW, Park YA, et al. Prognostic comparison between mucinous and nonmucinous adenocarcinoma in colorectal cancer. Medicine (Baltimore). 2015;94(15):e658. https:\/\/doi.org\/10.1097\/MD.0000000000000658.","journal-title":"Medicine (Baltimore)."},{"issue":"4","key":"18427_CR31","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1016\/j.clcc.2018.07.005","volume":"17","author":"M Khan","year":"2018","unstructured":"Khan M, Loree JM, Advani SM, et al. Prognostic implications of mucinous differentiation in metastatic colorectal carcinoma can be explained by distinct molecular and clinicopathologic characteristics. Clin Colorectal Cancer. 2018;17(4):e699\u2013709. https:\/\/doi.org\/10.1016\/j.clcc.2018.07.005.","journal-title":"Clin Colorectal Cancer."},{"issue":"8","key":"18427_CR32","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.21873\/anticanres.16530","volume":"43","author":"S Barat","year":"2023","unstructured":"Barat S, Wijayawardana R, Morris D. Outcomes for colorectal cancer cases with peritoneal metastases treated with cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy: a comparative analysis of survival between peritoneal carcinomatosis scores - PCI in a single centre. Anticancer Res. 2023;43(8):3529\u201338. https:\/\/doi.org\/10.21873\/anticanres.16530.","journal-title":"Anticancer Res."},{"issue":"12","key":"18427_CR33","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1016\/j.ejso.2020.07.039","volume":"46","author":"H Birgisson","year":"2020","unstructured":"Birgisson H, Enblad M, Artursson S, Ghanipour L, Cashin P, Graf W. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur J Surg Oncol. 2020;46(12):2283\u201391. https:\/\/doi.org\/10.1016\/j.ejso.2020.07.039.","journal-title":"Eur J Surg Oncol."},{"key":"18427_CR34","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fonc.2013.00262","volume":"3","author":"S Thies","year":"2013","unstructured":"Thies S, Langer R. Tumor regression grading of gastrointestinal carcinomas after neoadjuvant treatment. Front Oncol. 2013;3:262. https:\/\/doi.org\/10.3389\/fonc.2013.00262.","journal-title":"Front Oncol."},{"issue":"2","key":"18427_CR35","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1515\/pp-2016-0011","volume":"1","author":"W Solass","year":"2016","unstructured":"Solass W, Sempoux C, Detlefsen S, Carr NJ, Bibeau F. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS). Pleura Peritoneum. 2016;1(2):99\u2013107. https:\/\/doi.org\/10.1515\/pp-2016-0011.","journal-title":"Pleura Peritoneum."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18427-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-18427-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-18427-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T14:09:44Z","timestamp":1765289384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-18427-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["18427"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-18427-x","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"14 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}